Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$26.27
-$0.80(-3.25%)
At close: 4:00 PM EST
$26.27
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $27.80
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.80M
Market Cap
$5.24B
Enterprise Value$2.28B
Total Cash (Recent Filing)$521.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 18, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding201,476,530
10 Day Avg. Volume1,762,780
30 Day Avg. Volume1,804,238
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$37.00Price Target Upside40.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationIMVT-1402's deeper, dose-dependent IgG suppression compared with current therapies supports positioning as a potentially differentiated candidate across multiple autoimmune indications.
Competitive LandscapeDiscontinuation of a rival's Phase 3 program in thyroid eye disease reduces competitive pressure in the anti-FcRn field, improving the market opportunity for IMVT-1402.
Financing And RunwayA substantial financing raise strengthens the company's balance sheet and provides capital to advance late-stage programs toward potential commercialization.
Bears Say
Dosing RegimenSwitching from a higher to a lower dose during the primary endpoint period could dilute the observed treatment effect and complicate demonstration of sustained benefit.
Investor SentimentElevated short interest reflects pronounced investor skepticism, which could amplify share volatility and exert downward pressure on the stock.
Trial Design RiskAbsence of a pre-specified futility analysis in Phase 3 trials increases regulatory and execution risk if interim results diverge from expectations.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $27.80 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $5.24B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 18, 2026 which is in 31 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 10, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.714 by -$0.016.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.71.
How many shares outstanding does Immunovant have?
Immunovant has 201,476,530 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.714. Following the earnings report the stock price went up 0.086%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (40.85% Upside)
$37.00 (40.85% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $349.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.37%
12-Months-Change
Fundamentals
Return on Equity
-95.93%
Trailing 12-Months
Asset Growth
13.04%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant achievements in clinical trials, particularly for brepocitinib in dermatomyositis and batoclimab in Graves' disease, alongside a strong financial position and progress in legal proceedings. However, increasing competition in the Graves' disease market and delays in TED data release present challenges.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$37.00
▲(40.85% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---